By: Sara Riascos  Apr. 11, 2022

Major Joint Replacement is frequently associated with hospital readmission. Readmission is a hospital quality measure that reflects dimensions of quality of inpatient care and also impacts overall programs by payors such as CMS’s Star Rating Program, HRRP and Value-Based Purchasing. Eliquis (Apixaban) is an anticoagulant prescribed by doctors to reduce the risk of stroke caused by blood clots. Studies have shown that the early use of Eliquis (Apixaban) after a Major joint replacement surgery is associated with lower rates of clinically relevant bleeding. Other studies have shown that Eliquis reduces the risk of blood clots forming in lungs and legs after undergoing a Major Joint Replacement surgery.

By: Sara Riascos  Feb. 28, 2022

Major Joint Replacement is frequently associated with hospital readmission. Readmission is a hospital quality measure that reflects dimensions of quality of inpatient care and also impacts overall programs by payers such as CMS’s Star Rating Program, HRRP and Value-Based Purchasing. Eliquis(Apixaban) is an anticoagulant prescribed by doctors to reduce the risk of stroke caused by blood clots. Studies have shown that the early use of Eliquis (Apixaban) after a Major joint replacement surgery is associated with lower rates of clinically relevant bleeding. Other studies have shown that Eliquis reduces the risk of blood clots forming in lungs and legs after undergoing a Major Joint Replacement surgery. Dexur’s analysis of Real-World Evidence based on Medicare Claims data showed that the use of Eliquis(Apixaban) within 7 days of hospitalization was associated with lower hospital readmission rates for Major Joint Replacement at Ascension St. John Broken Arrow. Reduction in readmission rates helps hospitals improve their outcomes for various cost and quality programs. Dexur is an approved entity to perform Medicare claims data analysis, which it uses to perform quality outcomes analysis. Dexur has published several papers with Harvard Medical School on quality outcomes related topics. Dexur’s analysis of Drugs and their impact on quality outcomes, such as readmissions and mortality, are used by Hospitals, IDNs, and ACOs to implement best practices and manage Real World Evidence based risk factors.

By: Sara Riascos  Feb. 17, 2022

Major Joint Replacement is frequently associated with hospital readmission. Readmission is a hospital quality measure that reflects dimensions of quality of inpatient care and also impacts overall programs by payers such as CMS’s Star Rating Program, HRRP and Value-Based Purchasing. Eliquis (Apixaban) is an anticoagulant prescribed by doctors to reduce the risk of stroke caused by blood clots. Studies have shown that the early use of Eliquis (Apixaban) after a Major joint replacement surgery is associated with lower rates of clinically relevant bleeding. Other studies have shown that Eliquis reduces the risk of blood clots forming in lungs and legs after undergoing a Major Joint Replacement surgery. Dexur’s analysis of Real-World Evidence based on Medicare Claims data showed that the use of Eliquis (Apixaban) within 7 days of hospitalization was associated with lower hospital readmission rates for Major Joint Replacement at Cedars-Sinai Medical Center. Reduction in readmission rates helps hospitals improve their outcomes for various cost and quality programs. Dexur is an approved entity to perform Medicare claims data analysis, which it uses to perform quality outcomes analysis. Dexur has published several papers with Harvard Medical School on quality outcomes related topics. Dexur’s analysis of Drugs and their impact on quality outcomes, such as readmissions and mortality, are used by Hospitals, IDNs, and ACOs to implement best practices and manage Real World Evidence based risk factors.